Vicore Pharma

The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) on 11 May 2023.

Adoption of income statement and balance sheet for the financial year 2022 and discharge from liability

The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2022 as well as the balance sheet and consolidated balance sheet as of 31 December 2022. The members of the board of directors and the managing director were discharged from liability for the financial year 2022.

Allocation of profit or loss

The AGM resolved, in accordance with the board of directors’ proposal, that no dividend shall be paid for 2022 and that the results of the company shall be carried forward.

Election of board members and auditors, and fees to the board of directors and auditors

The AGM resolved, in accordance with the nomination committee’s proposal, to re-elect Jacob Gunterberg, Heidi Hunter, Maarten Kraan and Hans Schikan as well as new election of Michael Buschle and Elisabeth Björk as members of the board of directors for the period until the end of the next annual general meeting. Jacob Gunterberg was re-elected as the chairman of the board of directors. The audit firm EY AB was re-elected auditor of the company for the period until the end of the next annual general meeting.

The AGM further resolved on directors’ fees in accordance with the nomination committee’s proposal. The AGM further resolved, in accordance with the nomination committee’s proposal, that the fee to the auditor shall be paid as per approved statement of costs.

Approval of the board of directors’ remuneration report

The AGM resolved to approve the remuneration report presented by the board of directors.

Authorization to issue new shares

The AGM resolved in accordance with the board of directors’ proposal to authorize the board of directors to issue new shares, warrants and/or convertibles corresponding to not more than 20 per cent of the number of outstanding shares and votes at the time of the AGM.

Introduction of a share-based incentive program for the members of the board of directors

The AGM resolved in accordance with the nomination committee’s proposal to implement a share-based incentive program for members of the board of directors of the company, comprising not more than 120,000 share awards. It was further resolved, in accordance with the nomination committee’s proposal, to issue not more than 120,000 warrants in order to, at the end of the program, ensure delivery of shares to the participants.

Introduction of a long-term incentive program for the company’s senior management and key persons 

The AGM resolved in accordance with the board of directors’ proposal to implement a long-term incentive program for the senior management and key persons based on yearly grants of options. The total number of options that may be allocated to the participants amounts to not more than 5,000,000. It was further resolved, in accordance with the board of directors’ proposal, to issue not more than 5,000,000 warrants in order to ensure delivery of shares to the participants as well as, if necessary, related security costs.

Amendment of the articles of association

The AGM resolved in accordance with the board of directors’ proposal to amend the articles of association so that postal voting and collection of power of attorneys ahead of general meetings is enabled and the board of directors’ registered office is moved from Gothenburg to Stockholm.

Stockholm, 11 May 2023
Vicore Pharma Holding AB (publ)

For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
E-mail: carl-johan.dalsgaard@vicorepharma.com 

Hans Jeppsson, CFO
Phone: +46 70 553 14 65  
E-mail: hans.jeppsson@vicorepharma.com

The information was submitted for publication, through the agency of the contact persons set out above, on 11 May 2023 at 18:45 CEST.

About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life- changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG). Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets with long patent life for a variety of diseases, some of which could be partnered while others can be taken to the market by Vicore.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.